Today: 20 May 2026
Browse Category

NYSE:NVO 3 July 2025 - 9 October 2025

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk will acquire Akero Therapeutics for up to $5.2 billion, paying $54 per share in cash plus a potential $6 per share if Akero’s lead drug wins U.S. approval by 2031. Akero’s efruxifermin, in Phase 3 trials for fatty liver disease, has shown reversal of liver fibrosis in mid-stage studies. Akero shares jumped 19% on the news, while Novo shares were little changed. The deal is expected to close by year-end.
9 October 2025
··
Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

European stocks hit three-week lows Thursday, then rebounded Friday as the STOXX 600 fell 0.7% before rising 0.3%. U.S. President Trump’s new tariffs on drugs and trucks triggered a 2% drop in major pharma and truck stocks. The Bank of England warned on persistent UK inflation, while the ECB and Swiss National Bank held rates steady. Germany’s consumer confidence improved; Spain’s GDP beat forecasts.
26 September 2025
········
Weekend Science Bonanza: Breakthroughs From Space to Superbugs

Weekend Science Bonanza: Breakthroughs From Space to Superbugs

NASA confirmed its 6,000th exoplanet discovery, while astronomers observed a black hole speeding away at over 50 km/s after a merger. A weight-loss pill version of Ozempic led to 16% body weight loss in trials, and a quick EEG test detected early Alzheimer’s. Engineers nearly doubled refrigeration efficiency with nano-thin films. AI designed viruses that killed drug-resistant E. coli in lab tests.
21 September 2025
···
Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

A 2024 trial found liraglutide reduced brain shrinkage by about 50% and slowed cognitive decline in mild Alzheimer’s, but missed its main goal. Larger semaglutide trials are underway, with results expected in late 2025. A major exenatide trial in Parkinson’s showed no benefit, while ALS studies remain inconclusive. Pharmaceutical companies are expanding research into GLP-1 drugs for neurodegenerative diseases.
10 September 2025
·
Glowing Planets, Monster Blooms & a ‘Next Ozempic’ – Science Highlights (Sept 1–2, 2025)

Glowing Planets, Monster Blooms & a ‘Next Ozempic’ – Science Highlights (Sept 1–2, 2025)

Chemists unveiled a “4-in-1” obesity drug targeting four hormones for bariatric surgery-level weight loss, aiming to avoid Ozempic’s side effects. German neuroscientists traced early Alzheimer’s smell loss to immune cells destroying neural links. A study warns the Atlantic’s ocean circulation could collapse after 2100 under high emissions. The Great Atlantic Sargassum Belt hit a record 37.5 million tons, fouling beaches from Africa to the Gulf of Mexico.
2 September 2025
·
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

The U.S. administration fired CDC Director Dr. Susan Monarez after she resisted Health Secretary Robert F. Kennedy Jr.’s directives; four senior CDC officials resigned in protest, citing risks to young Americans and pregnant women. U.S. regulators approved updated COVID-19 vaccines for fall, but limited routine access to adults 65+ and high-risk groups, excluding healthy under-65s.
28 August 2025
····
Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

The FDA cleared Rocket Pharma to resume its gene therapy trial for Danon disease after a patient death halted the study in May; the trial will restart with a lower dose and without the immune-suppressing drug linked to the fatal complication. Rocket shares jumped over 30% after the decision. Early data showed Dynavax’s shingles vaccine matched GSK’s Shingrix in immune response but caused fewer side effects, sending Dynavax shares up 7%.
24 August 2025
···
Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Nvidia shares fell sharply on August 19, 2025, as a tech selloff pulled the Nasdaq down 1.5%. President Trump met Ukraine’s president and pledged U.S. support for Ukraine’s security in any peace deal. The U.S. Commerce Department expanded 232 tariffs to 407 new categories, affecting over $200 billion in imports. New Zealand’s central bank cut rates to 3.00%, sending the kiwi dollar to $0.584.
20 August 2025
········
Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

The FDA approved Tonix’s Tonmya as the first new fibromyalgia drug in over 15 years. Novo Nordisk’s Wegovy received accelerated FDA approval for MASH, becoming the first GLP-1 therapy cleared for the liver disease. Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, marking another setback after its $5.4 billion Global Blood Therapeutics acquisition. Eli Lilly announced a $1.3 billion AI drug partnership with Superluminal.
18 August 2025
·····
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
Global Business Pulse: Markets Juggle Tariffs, Rate Cuts & Mega-Deals (Aug 7–8, 2025)

Global Business Pulse: Markets Juggle Tariffs, Rate Cuts & Mega-Deals (Aug 7–8, 2025)

The United States imposed 100% tariffs on imported chips and electronics Aug. 7, sending Apple shares up 3%. Dow Jones fell 0.5%, S&P 500 slipped 0.1%, and Nasdaq hit a record, while Eli Lilly dropped 14% on weak drug data. The Bank of England cut rates for a fourth time, lifting the pound 0.7%. Paramount Global and Skydance completed an $8.4 billion merger.
8 August 2025
········
Digital Health & Telemedicine Industry Update (June–July 2025)

Digital Health & Telemedicine Industry Update (June–July 2025)

DispatchHealth and Medically Home merged in June 2025, creating one of the largest high-acuity hospital-at-home providers under the DispatchHealth name. Novo Nordisk ended its Wegovy deal with Hims & Hers Health in late June over compounded drug concerns, causing Hims & Hers shares to drop 30%. Teladoc Health shifted strategy after acquiring Catapult Health and UpLift earlier in the year.
3 July 2025
····
1 … 5 6 7

Stock Market Today

  • NextEra Shares Drop on $67 Billion Dominion Acquisition, Investors Wary of Premium and Debt
    May 20, 2026, 1:09 PM EDT. NextEra Energy's shares fell by up to 4.63% following its announcement of a $67 billion all-stock acquisition of Dominion Energy, marking one of the largest energy deals since ExxonMobil's 1998 merger. The offer includes a 23% premium over Dominion's prior close, at a time when utility stocks are already highly valued due to expected AI-driven electricity demand. Dominion shares surged about 9%. Investors express concern as the combined entity inherits over $150 billion in long-term debt, elevating refinancing risks amid rising interest rates. NextEra CEO John Ketchum defends the deal, citing enhanced scale to accelerate power development amid surging demand.

Latest articles

Exxon, Chevron Say Oil Reserves Hit by Hormuz Choke, More Volatility Ahead

Six Million Barrels Move Through Hormuz; Major Oil Risk Remains

20 May 2026
Three supertankers carrying 6 million barrels of Middle East crude exited the Strait of Hormuz on Wednesday after waiting over two months, shipping data showed. A fourth tanker was entering the waterway. Brent crude fell over 4% to $106.52 a barrel after President Trump said Iran talks were in “final stages.” The U.S. Navy warned the area remains “high risk” following recent ship attacks.
AAL Shares Rise as Oil Prices Fall

AAL Shares Rise as Oil Prices Fall

20 May 2026
American Airlines shares rose 6.9% to $12.89 midday Wednesday as airline stocks rallied with Brent crude down over 4% after President Trump said U.S.-Iran talks were in “final stages.” CEO Robert Isom will speak at Bernstein’s Strategic Decisions Conference on May 27. American expects to recover up to 85% of higher fuel costs by Q3. The company cut its 2026 outlook in April amid rising jet fuel prices.
Redwire draws attention after latest Army and NATO drone contracts

Redwire draws attention after latest Army and NATO drone contracts

20 May 2026
Redwire shares rose 0.6% to $13.99 after announcing a $15 million U.S. Army drone order and a multi-year NATO contract. The company’s first-quarter net loss widened to $76.5 million, despite revenue jumping 57.9% to $97 million. Redwire may sell up to $350 million in stock through an at-the-market program, according to a May 6 SEC filing.
Go toTop